Ophthalmic surgery (miosis): Intraocular: 0.5 mL instilled into anterior chamber before or after securing sutures
No dosage adjustment provided in manufacturer's labeling.
No dosage adjustment provided in manufacturer's labeling.
Refer to adult dosing.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intraocular [preservative free]:
Miostat: 0.01% (1.5 mL)
No
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intraocular:
Miostat: 0.01% (1.5 mL)
Intraocular: Do not inject >0.5 mL into the anterior chamber. Instillation may occur before or after securing sutures. Sterile technique must be used.
Ophthalmic surgery: To obtain miosis during cataract surgery and reduce intraocular pressure following cataract surgery.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Cardiovascular: Flushing
Central nervous system: Headache
Dermatologic: Diaphoresis
Gastrointestinal: Abdominal cramps, epigastric distress
Genitourinary: Bladder spasm
Ophthalmic: Corneal opacity, epithelial keratopathy, iritis, retinal detachment
<1%, postmarketing, and/or case reports: Blurred vision, corneal edema, eye irritation, eye pain, increased intraocular pressure, miosis, ocular hyperemia, visual impairment, vomiting
Hypersensitivity to carbachol or any component of the formulation.
Disease-related concerns:
• Asthma: Use with caution in patients with asthma.
• Gastrointestinal disease: Use with caution in patients with peptic ulcer disease or gastrointestinal spasm.
• Heart failure: Use with caution in patients with acute heart failure. In a scientific statement from the American Heart Association, ophthalmic cholinergic agents have been determined to be agents that may exacerbate underlying myocardial dysfunction (magnitude: minor) (AHA [Page 2016]).
• Hyperthyroidism: Use with caution in patients with hyperthyroidism.
• Parkinson disease: Use with caution in patients with Parkinson's disease.
• Urinary tract obstruction: Use with caution in patients with urinary tract obstruction.
Dosage form specific issues:
• Latex: Injection packaging may contain natural latex rubber.
None known.
Cyclopentolate: May diminish the therapeutic effect of Carbachol. Risk C: Monitor therapy
Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification
Reproduction studies have not been conducted.
It is not known if carbachol is excreted in breast milk. The manufacturer recommends that caution be exercised when administering carbachol to nursing women.
Synthetic direct-acting cholinergic agent that causes miosis by stimulating muscarinic receptors in the eye
Onset of action: Miosis: 2 to 5 minutes.
Solution (Miostat Intraocular)
0.01% (per mL): $31.51
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.